- Home
- NAAS vs FGEN Comparison
NAAS vs FGEN Comparison
Compare NAAS & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NAAS | FGEN |
|---|---|---|
| Founded | 2019 | 1993 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.8M | 35.6M |
| IPO Year | 2017 | 2014 |
Fundamental Metrics
Financial Performance| Metric | NAAS | FGEN |
|---|---|---|
| Price | $3.25 | $8.63 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $146.50 |
| AVG Volume (30 Days) | ★ 46.9K | 40.7K |
| Earning Date | 03-31-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 53.38 |
| Revenue | ★ $21,817,052.00 | $8,298,000.00 |
| Revenue This Year | $378.49 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $0.16 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.96 | $4.85 |
| 52 Week High | $40.32 | $21.94 |
Technical Indicators
Market Signals| Indicator | NAAS | FGEN |
|---|---|---|
| Relative Strength Index (RSI) | 40.75 | 47.05 |
| Support Level | $3.33 | $8.36 |
| Resistance Level | $3.60 | $9.19 |
| Average True Range (ATR) | 0.19 | 0.64 |
| MACD | -0.03 | 0.06 |
| Stochastic Oscillator | 28.18 | 16.59 |
Price Performance
Historical ComparisonAbout NAAS NaaS Technology Inc.
Naas Technology Inc is an electric vehicle charging service provider in China, whose vision is to power the world with carbon-neutral energy. It offers an integrated set of online solutions to charging station operators, a wide range of offline services that simplify the daily operations of charging station operators, and non-charging services such as food and beverage services to station operators.
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.